Gorbalenya Alexander E, Lieutaud Philippe, Harris Mark R, Coutard Bruno, Canard Bruno, Kleywegt Gerard J, Kravchenko Alexander A, Samborskiy Dmitry V, Sidorov Igor A, Leontovich Andrey M, Jones T Alwyn
Molecular Virology Laboratory, Department of Medical Microbiology, Center for Infectious Diseases, Leiden University Medical Center, P.O. Box 9600, E4-P, 2300 RC Leiden, The Netherlands.
Antiviral Res. 2010 Aug;87(2):95-110. doi: 10.1016/j.antiviral.2010.02.005. Epub 2010 Feb 11.
This review focuses on bioinformatics technologies employed by the EU-sponsored multidisciplinary VIZIER consortium (Comparative Structural Genomics of Viral Enzymes Involved in Replication, FP6 PROJECT: 2004-511960, active from 1 November 2004 to 30 April 2009), to achieve its goals. From the management of the information flow of the project, to bioinformatics-mediated selection of RNA viruses and prediction of protein targets, to the analysis of 3D protein structures and antiviral compounds, these technologies provided a communication framework and integrated solutions for steady and timely advancement of the project. RNA viruses form a large class of major pathogens that affect humans and domestic animals. Such RNA viruses as HIV, Influenza virus and Hepatitis C virus are of prime medical concern today, but the identities of viruses that will threaten human population tomorrow are far from certain. To contain outbreaks of common or newly emerging infections, prototype drugs against viruses representing the Virus Universe must be developed. This concept was championed by the VIZIER project which brought together experts in diverse fields to produce a concerted and sustained effort for identifying and validating targets for antivirus therapy in dozens of RNA virus lineages.
本综述聚焦于由欧盟资助的多学科VIZIER联盟(参与复制的病毒酶的比较结构基因组学,第六框架计划项目:2004 - 511960,2004年11月1日至2009年4月30日期间活跃)所采用的生物信息学技术,以实现其目标。从项目信息流的管理,到生物信息学介导的RNA病毒选择和蛋白质靶点预测,再到三维蛋白质结构和抗病毒化合物的分析,这些技术为项目的稳步及时推进提供了一个沟通框架和综合解决方案。RNA病毒构成了一大类影响人类和家畜的主要病原体。诸如人类免疫缺陷病毒、流感病毒和丙型肝炎病毒等RNA病毒是当今主要的医学关注点,但未来威胁人类群体的病毒种类还远不确定。为了控制常见或新出现感染的爆发,必须开发针对代表病毒库的病毒的原型药物。VIZIER项目倡导了这一理念,该项目汇聚了不同领域的专家,共同持续努力,为数十种RNA病毒谱系中抗病毒治疗靶点的识别和验证工作贡献力量。